Skip to main content
SpringerLink
Log in

Medical Treatment with Targeted Therapy for Metastatic Urothelial Bladder Carcinoma

  • Chapter
  • First Online:
Urinary Bladder Pathology

Abstract

Targeted therapeutic strategies are becoming a reality for patients with urothelial carcinoma. An FGFR inhibitor and an antibody drug conjugate gained FDA approval in 2019. In addition, there are other ongoing efforts to characterize distinct molecular subtypes of urothelial carcinoma (UC) that contain targetable genomic alterations. The future will see more studies to identify new targets, biomarkers of response, and mechanisms of resistance, thus leading to continued expansion of our strategies against UC. Here, we summarize the prominent strategies in targeted therapy for advanced-stage UC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. Epub 2020/01/09. https://doi.org/10.3322/caac.21590.

    Article  Google Scholar 

  2. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016;388(10061):2796–810. https://doi.org/10.1016/s0140-6736(16)30512-8.

    Article  PubMed  Google Scholar 

  3. NCI. Surveillance, epidemiology, and end results program. Cancer stat facts: bladder cancer 2018, cited 4 July 2018. Available from: https://seer.cancer.gov/statfacts/html/urinb.html

  4. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166(4):1296–9. Epub 2001/09/08

    Article  CAS  Google Scholar 

  5. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(18):1895–901. https://doi.org/10.1200/JCO.2013.53.2465. PubMed PMID: 24821881; PMCID: 4050203

    Article  CAS  Google Scholar 

  6. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(16):2171–7. Epub 2011/04/20. 10.1200/jco.2010.32.3139. PubMed PMID: 21502557; PMCID: PMC3107740

    Article  CAS  Google Scholar 

  7. Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, AS MC, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2018;36(19):1949–56. https://doi.org/10.1200/JCO.2017.75.0158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Jr., Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9):859–66. Epub 2003/08/29. https://doi.org/10.1056/NEJMoa022148349/9/859 [pii].

  9. Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, Trump DL, Natale RB, Grossman HB, Crawford ED. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104–9. https://doi.org/10.1002/cncr.24466.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S, Malmstrom PU. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–38. Epub 2011/12/23. https://doi.org/10.1016/j.eururo.2011.12.010.

    Article  PubMed  Google Scholar 

  11. Network NCC. Clinical practice guidelines in oncology: bladder cancer 2019, updated 7/10/19; cited 2019 8/1/19; Version 4.2019: NCCN clinical practice guidelines in oncology: bladder cancer, 2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

  12. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Rovira PS, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; (0732-183X (Print))

    Google Scholar 

  13. Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee K-W, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, Rosen G, Gulley JL, Apolo AB. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51–64. https://doi.org/10.1016/S1470-2045(17)30900-2.

    Article  CAS  PubMed  Google Scholar 

  14. Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3(9):e172411. https://doi.org/10.1001/jamaoncol.2017.2411.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/S0140-6736(16)00561-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590–8. Epub 2016/10/14. https://doi.org/10.1016/s1470-2045(16)30496-x. PubMed PMID: 27733243; PMCID: PMC5648054

  17. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP. Teng S-l, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558. https://doi.org/10.1038/nature13904.

    Article  CAS  PubMed  Google Scholar 

  18. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35(19):2117–24. https://doi.org/10.1200/JCO.2016.71.6795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–92. https://doi.org/10.1016/S1470-2045(17)30616-2.

    Article  CAS  PubMed  Google Scholar 

  20. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMoa1613683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12(6):719–39. Epub 2017/11/09. https://doi.org/10.1007/s11523-017-0535-0.

    Article  PubMed  Google Scholar 

  22. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, Bochner BH, Reuter VE, Bajorin DF, Milowsky MI, Taylor BS, Solit DB. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(25):3133–40. Epub 2013/07/31. https://doi.org/10.1200/jco.2012.46.5740. PubMed PMID: 23897969; PMCID: PMC3753703.

  23. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–56.e25. Epub 2017/10/11. https://doi.org/10.1016/j.cell.2017.09.007. PubMed PMID: 28988769; PMCID: PMC5687509.

  24. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O’Hagan A, Avadhani A, Siefker-Radtke AO. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–48. https://doi.org/10.1056/NEJMoa1817323.

    Article  CAS  PubMed  Google Scholar 

  25. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(7):400–10. https://doi.org/10.1038/nrurol.2014.129.

    Article  CAS  PubMed  Google Scholar 

  26. McConkey DCW, Shen Y, Lee I, Porten S, Matin S, Kamat A, Corn P, Millikan R, Dinney C, Czerniak B, Siefker-Radtke A. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial Cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol. 2016;69:855–62.

    Article  CAS  Google Scholar 

  27. McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CP. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am 2015;29(2):377–94, x–xi. Epub 2015/04/04. https://doi.org/10.1016/j.hoc.2014.11.003.

  28. Choi W, Porten S, Kim S, Willis D, Plimack Elizabeth R, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney Colin PN, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. https://doi.org/10.1016/j.ccr.2014.01.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Vlachostergios PJ, Jakubowski CD, Niaz MJ, Lee A, Thomas C, Hackett AL, Patel P, Rashid N, Tagawa ST. Antibody-drug conjugates in bladder cancer. Bladder Cancer (Amsterdam, Netherlands). 2018;4(3):247–59. https://doi.org/10.3233/BLC-180169.

    Article  PubMed Central  Google Scholar 

  30. Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies Current opinion in oncology 2019. Epub 2019/03/08. https://doi.org/10.1097/cco.0000000000000532.

  31. Samanta D, Almo SC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci 2015;72(4):645–58. Epub 2014/10/20. https://doi.org/10.1007/s00018-014-1763-4.

  32. Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VHJ, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB, Cichutek K, von Messling V, Lopez M, Cattaneo R. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480:530. https://doi.org/10.1038/nature10639.; https://www.nature.com/articles/nature10639#supplementary-information.

  33. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol. 2010;134(5):835–45. Epub 2010/10/21. https://doi.org/10.1309/ajcpgxk0fr4mhihb. PubMed PMID: 20959669; PMCID: PMC3042138.

  34. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem. 2005;280(20):19543–50. Epub 2005/03/24. https://doi.org/10.1074/jbc.M410943200.

    Article  CAS  PubMed  Google Scholar 

  35. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69(16):6694–703. Epub 2009/08/15. https://doi.org/10.1158/0008-5472.Can-09-0016.

    Article  CAS  PubMed  Google Scholar 

  36. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avina H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Donate F, Morrison K, Stover DR. Enfortumab Vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical Cancer models. Cancer Res. 2016;76(10):3003–13. Epub 2016/03/26. https://doi.org/10.1158/0008-5472.Can-15-1313.

    Article  CAS  PubMed  Google Scholar 

  37. Rosenberg JE, Sridhar SS, Zhang J, Smith DC, Ruether JD, Flaig TW, Baranda JC, Lang JM, Plimack ER, Sangha RS, Heath EI, Merchan JR, Quinn DI, Srinivas S, Milowsky MI, Wu C, Gartner EM, Melhem-Bertrandt A, Petrylak DP. Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC). J Clin Oncol. 2018;36(15_suppl) https://doi.org/10.1200/JCO.2018.36.15_suppl.4504.

  38. Rosenberg JE, Sridhar SS, Zhang J, Smith DC, Ruether JD, Flaig TW, Baranda JC, Lang JM, Plimack ER, Sangha RS, Heath EI, Merchan JR, Quinn DI, Srinivas S, Milowsky MI, Wu C, Gartner EM, Melhem-Bertrandt A, Petrylak DP. Mature results from EV-101: a phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC). J Clin Oncol. 2019;37(7_suppl):377. https://doi.org/10.1200/JCO.2019.37.7_suppl.377.

    Article  Google Scholar 

  39. Rosenberg JE, Heath EI, O’Donnell PH, Hahn NM, Balar AV, Gartner EM, Melhem-Bertrandt A, Petrylak DP. EV-201 study: a single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy. J Clin Oncol. 2018;36(15_suppl):TPS4590-TPS. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS4590.

  40. Rosenberg JE, Flaig TW, Friedlander TW, Milowsky MI, Srinivas S, Petrylak DP, Merchan JR, Bilen MA, Carret A-S, Yuan N, Sasse C, Hoimes CJ. Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2020;38(6_suppl):441. https://doi.org/10.1200/JCO.2020.38.6_suppl.441.

    Article  Google Scholar 

  41. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6(3–4):84–105. https://doi.org/10.18632/genesandcancer.40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59(7):701–10. Epub 2011/05/10. https://doi.org/10.1369/0022155411410430. PubMed PMID: 21551320; PMCID: PMC3201164.

  43. Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, Lattanzio R, de Lange R, Weidle UH, Piantelli M, Alberti S. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222–33. Epub 2012/02/22. https://doi.org/10.1038/onc.2012.36.

    Article  CAS  PubMed  Google Scholar 

  44. Avellini C, Licini C, Lazzarini R, Gesuita R, Guerra E, Tossetta G, Castellucci C, Giannubilo SR, Procopio A, Alberti S, Mazzucchelli R, Olivieri F, Marzioni D. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8(35):58642–53. Epub 2017/09/25. https://doi.org/10.18632/oncotarget.17407. PubMed PMID: 28938585; PMCID: PMC5601681.

  45. Lin H, Huang JF, Qiu JR, Zhang HL, Tang XJ, Li H, Wang CJ, Wang ZC, Feng ZQ, Zhu J. Significantly upregulated TACSTD2 and cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol. 2013;94(1):73–8. Epub 2012/10/04. https://doi.org/10.1016/j.yexmp.2012.08.004.

    Article  CAS  PubMed  Google Scholar 

  46. Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, Sacituzumab Govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870. https://doi.org/10.1158/1078-0432.CCR-14-3321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human Cancer xenograft models and monkeys. Clin Cancer Res. 2011;17(10):3157.

    Article  CAS  Google Scholar 

  48. Tagawa ST, Faltas BM, Lam ET, Saylor PJ, Bardia A, Hajdenberg J, Morgans AK, Lim EA, Kalinsky K, Simpson PS, Galsky MD, Goswam T, Wegener WA, Petrylak DP. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I/II study. J Clin Oncol. 2019;37(7_suppl):354. https://doi.org/10.1200/JCO.2019.37.7_suppl.354.

    Article  Google Scholar 

  49. Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123(19):3843–54. https://doi.org/10.1002/cncr.30789.

    Article  CAS  PubMed  Google Scholar 

  50. Morrison K, Challita-Eid PM, Raitano A, An Z, Yang P, Abad JD, Liu W, Lortie DR, Snyder JT, Capo L, Verlinsky A, Aviña H, Doñate F, Joseph IBJ, Pereira DS, Morrison K, Stover DR. Development of ASG-15ME, a novel antibody–drug conjugate targeting SLITRK6, a new urothelial cancer biomarker. Mol Cancer Ther. 2016;15(6):1301.

    Article  CAS  Google Scholar 

  51. Melhem-Bertrandt A, Morgans AK, Anand B, Eigl BJ, Petrylak D, Gartner E, Heath E, Yu EY, Sonpavde G, Picus J, Morrison K, Jackson L, Vincent M, Chu R, Cheng S, George S, Hotte SJ. Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Ann Oncol. 2016;27(suppl_6). https://doi.org/10.1093/annonc/mdw373.08.

  52. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3(3):264–79. Epub 2013/02/19. https://doi.org/10.1158/2159-8290.Cd-12-0362.

    Article  CAS  PubMed  Google Scholar 

  53. di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012;2012:10. https://doi.org/10.1155/2012/429213.

    Article  Google Scholar 

  54. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23:18. https://doi.org/10.1038/12615.

    Article  CAS  PubMed  Google Scholar 

  55. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22(4):795–803. Epub 2012/11/24. https://doi.org/10.1093/hmg/dds486. PubMed PMID: 23175443; PMCID: PMC3554204.

  56. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045–56. Epub 2012/03/01. https://doi.org/10.1158/0008-5472.Can-11-3034.

    Article  CAS  PubMed  Google Scholar 

  57. Powles T, Balar A, Gravis G, Jones R, Ravaud A, Florence J, Grivas P, Petrylak DP, Galsky M, Carles J, Sridhar S, Arkenau H-T, Carroll D, DeCesare J, Mercier F, Hodgson D, Stone J, Cosaert J, Landers D. 902O An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies. Ann Oncol. 2019;30(Supplement_5). https://doi.org/10.1093/annonc/mdz249.001.

  58. Milowsky MI, Dittrich C, Duran I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer (Oxford, England: 1990). 2014;50(18):3145–52. Epub 2014/12/03. https://doi.org/10.1016/j.ejca.2014.10.013.

  59. FDA website [Internet]. TFaDA. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma

  60. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(30):3401–8. Epub 2015/09/02. https://doi.org/10.1200/jco.2014.60.7341.

  61. Joerger M, Cassier PA, Penel N, Cathomas R, Richly H, Schostak M, Janitzky A, Wermke M, Nogova L, Tai DW-M, Sayehli C, Grüllich C, Grande E, Navarro A, Park SH, Nogai H, Bender S, Ellinghaus P, Schuler MH. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. J Clin Oncol. 2018;36(15_suppl):4513. https://doi.org/10.1200/JCO.2018.36.15_suppl.4513.

    Article  Google Scholar 

  62. Sequist LV, Cassier P, Varga A, Tabernero J, Schellens JH, Delord J-P, LoRusso P, Camidge DR, Medina MH, Schuler M, Campone M, Tian GG, Wong S, Corral J, Isaacs R, Sen SK, Porta DG, Kulkarni SG, Lefebvre C, Wolf J. Abstract CT326: phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res. 2014;74(19 Supplement):CT326-CT. https://doi.org/10.1158/1538-7445.Am2014-ct326.

  63. Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grunwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 Inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018;8(7):812–21. Epub 2018/06/01. https://doi.org/10.1158/2159-8290.Cd-18-0229.

  64. Necchi A, Pouessel D, Leibowitz-Amit R, Flechon A, Gupta S, Barthelemy P, Maio M, Zhu X, Asatiani E, Serbest G, Zhen H, Loriot Y. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). Ann Oncol. 2018;29:viii319–viii20. https://doi.org/10.1093/annonc/mdy283.109.

    Article  Google Scholar 

  65. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN, Jr., Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(16):2218–24. Epub 2007/06/01. https://doi.org/10.1200/jco.2006.08.0994.

  66. Oudard S, Culine S, Vano Y, Goldwasser F, Theodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer (Oxford, England: 1990). 2015;51(1):45–54. Epub 2014/12/03. https://doi.org/10.1016/j.ejca.2014.10.009.

  67. Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J, Hilman S, Beresford M, Macdonald G, Santhanam S, Frew JA, Stockdale A, Hughes S, Berney D, Chowdhury S. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(1):48–55. Epub 2016/12/31. https://doi.org/10.1200/jco.2015.66.3468.

  68. Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, 3rd, Karrison T, Stadler WM, Nakamura Y, O’Donnell PH. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(18):2165–71. Epub 2016/04/06. https://doi.org/10.1200/jco.2015.66.3047. PubMed PMID: 27044931; PMCID: PMC5569685.

  69. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Jr., Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–194. Epub 2018/02/09. https://doi.org/10.1038/nature25475. PubMed PMID: 29420467; PMCID: PMC5808581.

  70. Li BT, Makker V, Buonocore DJ, Offin MD, Olah ZT, Panora E, Shen R, Ho AL, Yaeger R, Iyer G, Ginsberg MS, Ulaner G, Solit DB, Hyman DM, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol. 2018;36(15_suppl):2502. https://doi.org/10.1200/JCO.2018.36.15_suppl.2502.

    Article  Google Scholar 

  71. Kiss B, Wyatt AW, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Buerki C, Davicioni E, Collins C, Thalmann GN, Black PC, Seiler R. Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy. Sci Rep. 2017;7:42713. https://doi.org/10.1038/srep42713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer. 2011;104(1):75–82. https://doi.org/10.1038/sj.bjc.6606016.

    Article  CAS  PubMed  Google Scholar 

  73. Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16(6):1010–1020. Epub 2017/03/28. https://doi.org/10.1158/1535-7163.Mct-16-0589.

  74. Collin M-P, Lobell M, Hübsch W, Brohm D, Schirok H, Jautelat R, Lustig K, Bömer U, Vöhringer V, Héroult M, Grünewald S, Hess-Stumpp H. Discovery of Rogaratinib (BAY 1163877): a pan-FGFR inhibitor. ChemMedChem. 2018;13(5):437–45. https://doi.org/10.1002/cmdc.201700718.

    Article  CAS  PubMed  Google Scholar 

  75. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, Wartmann M, Berghausen J, Drueckes P, Zimmerlin A, Bussiere D, Murray J, Graus Porta D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54(20):7066–7083. Epub 2011/09/23. https://doi.org/10.1021/jm2006222.

  76. Liu PCC, Wu L, Koblish H, Bowman K, Zhang Y, Klabe R, Leffet L, DiMatteo D, Rupar M, Gallagher K, Hansbury M, Zhang C, He C, Collier P, Covington M, Wynn R, Yeleswaram S, Vaddi K, Burn T, Yao W, Huber R, Scherle P, Hollis G. Abstract 771: preclinical characterization of the selective FGFR inhibitor INCB054828. Cancer Res. 2015;75(15 Supplement):771. https://doi.org/10.1158/1538-7445.AM2015-771.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Omar Alhalabi

  2. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jianjun Gao

Authors
  1. Omar Alhalabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianjun Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianjun Gao .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Haijun Zhou

  2. Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo

  3. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Jae Y. Ro

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Alhalabi, O., Gao, J. (2021). Medical Treatment with Targeted Therapy for Metastatic Urothelial Bladder Carcinoma. In: Zhou, H., Guo, C.C., Ro, J.Y. (eds) Urinary Bladder Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-71509-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71509-0_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71508-3

  • Online ISBN: 978-3-030-71509-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation